Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical device information exchange: further talks ahead:

This article was originally published in Clinica

Executive Summary

The European Commission's working group on transparency is meeting on March 14 to discuss two papers on communication exchange, one prepared by member state experts and the other by industry. The member state text, put forward by the UK authorities at the competent authorities meeting in January, where it was endorsed, covers the exchange of information between competent authorities. It examines what information should be requested from notified bodies and how this information should be shared. The industry paper concerns the contents of information that is to be provided to the public and the flow of commercially sensitive information. While the authority paper is well advanced, the industry text will represent a first position on this issue.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT061374

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel